Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "BofA-Securities"

3 News Found

Lonza to buy US biologics site from Roche for US$ 1.2 billion
Biotech | March 20, 2024

Lonza to buy US biologics site from Roche for US$ 1.2 billion

Lonza plans to invest approximately CHF 500 million to upgrade the facility

Emcure Pharma files DRHP for proposed IPO, offer size in the range Rs 4,500-5000 crores
News | August 20, 2021

Emcure Pharma files DRHP for proposed IPO, offer size in the range Rs 4,500-5000 crores

In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y

Glenmark Life Sciences IPO to open on July 27, 2021
News | July 26, 2021

Glenmark Life Sciences IPO to open on July 27, 2021

The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration

Latest Stories

WACKER expands production capacity for biopharmaceuticals in San Diego

Sumitomo Corporation makes full-scale entry into private clinic business in fast-growing southeast Asia

AstraZeneca’s Calquence combination regimen demonstrated positive results in 1st-line mantle cell lymphoma in ECHO Phase III trial

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
Vinod Paremal President & MD, Evonik, India Region

Packaging